Predetermined Change Control Plan (PCCP): The Regulatory Blueprint Every AI/ML Medical Device Company Needs

Why the PCCP Is Now a Strategic Imperative for AI/ML Device Makers

If your company is developing an artificial intelligence or machine learning-based Software as a Medical Device (AI/ML SaMD), you already know the core regulatory tension: your algorithm is designed to learn and improve over time, but FDA's traditional change control framework was built for static devices. Every meaningful algorithm update could theoretically trigger a new 510(k), PMA supplement, or De Novo submission -- creating a cycle that kills your product's competitive advantage before it ever reaches patients.

The Predetermined Change Control Plan (PCCP) is FDA's answer to this problem. Used correctly, it is one of the most powerful regulatory tools available to AI/ML device developers today. Used incorrectly -- or ignored entirely -- it can become a costly compliance liability.

What Is a PCCP and Where Does It Live in the Regulatory Framework?

A PCCP is a documented plan, submitted as part of a marketing submission, that describes anticipated future modifications to an AI/ML device and the methodology by which those modifications will be implemented, validated, and monitored -- without requiring a new premarket submission for each change.

The statutory authority for PCCPs was formalized under Section 3308 of the Food and Drug Omnibus Reform Act (FDORA) of 2022, which amended Section 515C of the Federal Food, Drug, and Cosmetic Act. FDA subsequently issued its final guidance, 'Marketing Submission Recommendations for a Predetermined Change Control Plan for Artificial Intelligence-Enabled Device Software Functions,' finalized in December 2024. This guidance is the governing document your regulatory team must be working from today.

PCCPs can be included in 510(k), PMA, De Novo, and Humanitarian Device Exemption (HDE) submissions, as well as supplements to previously approved applications. The plan travels with the device's authorization -- meaning once FDA approves your PCCP, you have a pre-negotiated runway for iterative development.

The Three Core Components FDA Expects to See

FDA's guidance outlines a clear structure. A well-constructed PCCP must include three substantive elements:

• Description of Planned Modifications: You must clearly articulate the specific types of changes anticipated -- such as retraining on expanded datasets, changes to model architecture, or updates to intended use populations. Vague language like 'performance improvements' will not satisfy FDA reviewers. Be specific about the scope and boundaries of each modification type.
• Modification Protocol: This is the technical and procedural heart of your PCCP. It must describe the data management practices, retraining procedures, performance evaluation methods, and statistical validation approaches you will use to implement each planned modification. Your protocol should reference recognized standards where applicable, including ISO 13485 quality management requirements and relevant IEC 62304 software lifecycle processes.
• Impact Assessment: For each planned modification, you must demonstrate that you have evaluated the potential impact on device safety and effectiveness. This includes an analysis of how the change could affect algorithm performance, introduce new failure modes, or shift the benefit-risk profile for the intended patient population.

Common Mistakes That Get PCCPs Rejected or Flagged

Having reviewed and supported numerous AI/ML submissions, ADB Consulting sees the same patterns repeatedly derail otherwise strong PCCP packages:

• Overly broad modification scope: Attempting to cover every possible future change under a single PCCP umbrella signals to FDA that you have not conducted rigorous upfront risk analysis. Reviewers will push back.
• Weak SaMD Risk Categorization: Your PCCP must be calibrated to your device's risk level under the SaMD risk framework. A Class II diagnostic tool and a Class III treatment-influencing algorithm carry fundamentally different PCCP expectations. Applying a one-size-fits-all template is a red flag.
• Missing performance thresholds: Your modification protocol must include objective, pre-specified performance benchmarks -- not subjective language like 'acceptable performance.' FDA expects quantitative criteria tied to clinically meaningful endpoints.
• Disconnected post-market surveillance plan: A PCCP does not eliminate post-market obligations; it integrates with them. Your Real-World Performance Monitoring plan must be explicitly linked to your PCCP, showing how field data will trigger or constrain future modifications. This aligns with FDA's broader emphasis on 21 CFR Part 820 quality system requirements and the 2023 AI/ML Action Plan commitments.

Integrating the PCCP Into Your Regulatory Strategy Early

The single most expensive mistake a startup can make is treating the PCCP as a late-stage add-on. The modification boundaries you define in your PCCP directly shape your device architecture, your clinical and analytical validation study design, and your quality system infrastructure. If those decisions have already been locked in without PCCP considerations, retrofitting compliance becomes an expensive and time-consuming exercise.

Smart companies are building PCCP strategy into their design history file (DHF) structure from day one -- mapping anticipated algorithm lifecycle phases against regulatory touchpoints before a single line of production code is written. This is where experienced regulatory counsel pays for itself many times over.

What Comes Next for PCCP Regulation

FDA has signaled continued evolution in this space. The agency's ongoing work through the Digital Health Center of Excellence and the Total Product Life Cycle (TPLC) framework will further refine expectations for AI/ML transparency, bias monitoring, and real-world algorithm performance reporting. Companies that build adaptable, well-documented PCCPs today are positioning themselves favorably for the regulatory environment of the next five years.

Ready to Build a PCCP That Actually Holds Up to FDA Review?

At ADB Consulting and CRO Inc., Andre Butler and the team have deep hands-on experience developing AI/ML regulatory strategies and preparing PCCP packages that align with FDA expectations -- not just checkbox compliance. Whether you are preparing your first 510(k) for an AI-enabled device or filing a PMA supplement with a PCCP component, we bring the technical and regulatory depth to do it right the first time.

Book your free discovery call today at adbccro.com and let us help you turn your AI/ML innovation into a compliant, market-ready product.